단순 헤르페스 : 시장 인사이트, 역학 및 시장 예측(2036년)

Herpes Simplex Insights and Trends

• Herpes Simplex Virus (HSV) infection is caused by two viral types, HSV-1 and HSV-2, which are responsible for oral and genital herpes infections, respectively. The disease is characterized by lifelong viral latency with intermittent reactivation, resulting in recurrent symptomatic outbreaks and continued transmission risk.
• The prevalence of HSV remains high globally, particularly among sexually active adults and immunocompromised individuals. Disease recurrence and transmission are influenced by factors such as immune status, stress, hormonal changes, ultraviolet exposure, and close physical contact. Increasing use of molecular diagnostic techniques, particularly PCR-based assays, has improved diagnostic accuracy and supported earlier identification of HSV infections.
• Current treatment is primarily based on antiviral agents including valacyclovir, and famciclovir, which remain the standard of care for suppressive and episodic therapy. These therapies reduce viral replication, shorten outbreak duration, and lower recurrence frequency; however, they do not eliminate latent infection, and recurrent disease remains a major clinical challenge.
• The HSV treatment landscape is witnessing gradual innovation with the development of helicase-primase inhibitors such as Pritelivir, ABI-5366, ABI-1179, and Adibelivir (IM-250), which are being investigated to address antiviral resistance, improve long-term viral suppression, and provide differentiated mechanisms compared with conventional nucleoside analogs.
• Beyond antiviral therapies, pharmaceutical and biotechnology companies are also evaluating therapeutic vaccines, mRNA-based approaches, monoclonal antibodies, and gene-editing technologies aimed at improving immune control and targeting latent viral reservoirs. These emerging approaches are expected to shape the future HSV treatment paradigm over the forecast period.
• Despite the availability of effective symptomatic therapies, major unmet needs persist in HSV management, including the absence of curative treatment, continued asymptomatic viral shedding, recurrent disease burden, and the emergence of resistant HSV infections in immunocompromised populations.

DelveInsight's 'Herpes Simplex- Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology, as well as the Herpes Simplex market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Herpes Simplex market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, Herpes Simplex patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Herpes Simplex and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Herpes Simplex Market

Chronic, Recurrent Nature Driving Long-Term Treatment Use

HSV establishes lifelong latency with periodic reactivation, leading to recurrent oral and genital lesions. This chronic nature drives continuous use of suppressive therapies such as Valacyclovir, supporting a stable and recurring treatment market rather than one-time therapy demand.

Increasing Awareness, Diagnosis, and Screening

Improved sexual health awareness, wider access to diagnostic testing, and public health initiatives are increasing HSV diagnosis rates particularly for genital herpes (HSV-2). This trend is especially notable in developed markets like the United States, where screening and physician consultations are contributing to higher treatment uptake.

Growing Demand for Convenient and Patient-Friendly Therapies

There is increasing preference for simplified dosing regimens and novel formulations. Drugs like Valacyclovir (once/twice daily) are localized options highlighting the shift toward convenience, which improves adherence and expands market utilization.

Emerging Pipeline and Novel Mechanisms of Action

Innovation beyond traditional nucleoside analogs is gaining traction. Pipeline agents such as Pritelivir (a helicase primase inhibitor) demonstrate potential efficacy in drug-resistant HSV, creating opportunities for differentiated therapies and premium pricing segments.

Herpes Simplex Understanding and Treatment Algorithm

Herpes Simplex Overview and Diagnosis

HSV is a lifelong viral infection caused by HSV-1 and HSV-2. HSV-1 primarily causes oral herpes (cold sores), while HSV-2 is mainly associated with genital herpes, characterized by painful lesions and discomfort. The virus spreads through direct contact with infected secretions during oral, genital, or anal contact, and can also be transmitted via kissing or from mother to newborn during childbirth.

Diagnosis of HSV is based on clinical evaluation supported by laboratory testing. PCR is the most sensitive method for detecting HSV DNA from lesions, while viral culture may be used in certain cases. Serologic testing helps identify prior exposure and differentiate between HSV-1 and HSV-2, particularly in asymptomatic individuals.

Current Herpes Simplex Treatment Landscape

The treatment of HSV focuses on symptom control, reducing recurrence, and limiting transmission, as no curative therapy exists. Antiviral nucleoside analogs such as Valacyclovir, and Famciclovir are the mainstay, acting by inhibiting viral DNA replication.

Treatment includes episodic therapy for acute outbreaks and suppressive therapy for patients with frequent recurrences. Topical agents like Penciclovir and Docosanol are used for herpes labialis, while resistant cases may require agents such as Foscarnet. Supportive care and patient education remain important components of management.

Herpes Simplex Unmet Needs

The section "unmet needs of Herpes Simplex " outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Lack of curative therapy

2. Absence of an effective vaccine

3. Management of recurrent and resistant infections

4. Underdiagnosis and social stigma, and others.....

Herpes Simplex Epidemiology

Key Findings from Herpes Simplex Epidemiological Analysis and Forecast

• According to the World Health Organization, HSV-1 infection is highly prevalent globally, with a large proportion of the population acquiring the infection during childhood, often through non-sexual contact.
• Globally, HSV-2 remains a major cause of genital herpes, affecting hundreds of millions of individuals, with a higher burden observed in women compared to men.
• HSV infections are lifelong and characterized by periods of latency and reactivation, contributing to recurrent disease and sustained transmission within populations.
• A significant proportion of HSV infections remain asymptomatic or unrecognized, leading to underdiagnosis and continued spread of the virus.
• The incidence of HSV-2 infection remains substantial worldwide, particularly among sexually active populations, with younger adults at higher risk of acquisition.
• In the United States, epidemiological studies indicate a considerable burden of both HSV-1 and HSV-2 infections, with notable gender disparities and higher prevalence in females.
• Across the EU4 and the UK, the total gender-specific cases of herpes simplex showed a higher prevalence among females, accounting for approximately 55% of cases, compared to around 45% among males.
• The prevalence of recurrent herpes simplex cases in Japan showed HSV-2 accounted for over ~70%, with HSV-1 following at ~30%.

Herpes Simplex Drug Analysis & Competitive Landscape

The Herpes Simplex drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I/II-II clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the herpes simplex treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the herpes simplex therapeutics market.

Approved Therapies for Herpes Simplex

Amenamevir (AMENALIEF): Maruho

Amenamevir (AMENALIEF), developed and commercialized by Maruho, is an oral helicase-primase inhibitor approved in Japan for the treatment of recurrent herpes simplex and herpes zoster. Unlike conventional nucleoside analog antivirals, AMENALIEF targets the herpesvirus helicase-primase complex, an essential enzyme for viral DNA replication, offering a novel mechanism of antiviral activity in HSV management.

Herpes Simplex Pipeline Analysis

Pritelivir (AIC-316): AiCuris

Pritelivir (AIC-316) by AiCuris Anti-infective Cures AG is is an innovative, therapeutic candidate inhibiting HSV replication, currently being evaluated in a pivotal Phase III trial for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. In immunocompromised patients, HSV symptoms are more severe and include disseminated disease, keratitis, and encephalitis; resistances to marketed drugs are often described.

ABI-5366: Assemblybio

ABI-5366, developed by Assemblybio , is a long-acting HSV helicase-primase inhibitor in Phase Ib development for recurrent genital herpes. The therapy targets the HSV helicase-primase complex, a validated antiviral mechanism, and has demonstrated reductions in viral shedding and genital lesion rates with potential for once-weekly oral dosing.

Herpes Simplex Key Players, Market Leaders and Emerging Companies

• Maruho
• Aicuris
• Assembly Biosciences
• Innovative Molecules, and others

Herpes Simplex Drug Updates

• As of April 2026, Assembly Biosciences announced that Phase Ib clinical data for its HSV helicase primase inhibitor candidates, ABI-5366 and ABI-1179, was presented at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Munich, Germany.
• In April 2026, AiCuris announced that the US Food and Drug Administration (FDA) has granted Priority Review designation to the New Drug Application (NDA) for pritelivir for the treatment of refractory HSV infection, with or without resistance, in immunocompromised patients. The NDA submission was supported by initial results from the pivotal Phase III clinical trial, in which pritelivir achieved its registrational primary endpoint. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in the fourth quarter of 2026.
• According to the AiCuris corporate presentation, market approval for the Pritelivir (AIC-316) is targeted in the second half of 2026.

Herpes Simplex Market Outlook

The HSV treatment market is evolving beyond the long-established use of nucleoside analog antivirals such as valacyclovir, and famciclovir, which have remained the standard of care for episodic and suppressive treatment for decades. Generic antivirals, particularly generic valacyclovir, acyclovir, and famciclovir, continue to account for a substantial share of the HSV treatment market due to their established efficacy, widespread availability, and lower treatment costs. The broad utilization of these low-cost generics has increased market competition and created pricing pressure for branded therapies, while maintaining nucleoside analog antivirals as the cornerstone of episodic and suppressive HSV management.

Recent pipeline advancements have positioned helicase primase inhibition as a promising next-generation strategy in HSV treatment. Pritelivir (AiCuris), an investigational oral helicase-primase inhibitor, demonstrated positive Phase III results in refractory HSV infections in immunocompromised patients and has received FDA Priority Review, with a PDUFA target date in the fourth quarter of 2026. Additional candidates including ABI-5366, ABI-1179, and Adibelivir (IM-250) are also progressing through clinical development with the goal of improving antiviral potency, durability, and dosing convenience.

Despite growing innovation, the HSV vaccine landscape has experienced significant setbacks. discontinued development of its recombinant HSV vaccine candidate, GSK3943104, after a Phase II study failed to meet the primary endpoint of reducing recurrent genital herpes episodes. Subsequently, Moderna also terminated development of its mRNA-based therapeutic HSV vaccine candidate, mRNA-1608, deciding not to advance the program into Phase III testing following completion of a Phase I/II study. These discontinuations highlight the scientific and clinical challenges associated with HSV vaccine development, leaving as the only major biopharma company with an active HSV vaccine program currently in clinical development.

Beyond antiviral agents, the HSV landscape is increasingly incorporating therapeutic vaccines, mRNA-based therapies, and gene-editing approaches aimed at achieving long-term viral control and addressing latent infection. Overall, continued innovation in mechanism-based therapies and expanding pipeline activity are expected to drive future growth and reshape the HSV treatment landscape over the coming years.

• The US is expected to remain the largest HSV treatment market, driven by high disease awareness, established antiviral utilization, advanced healthcare infrastructure, and increasing investment in next-generation HSV therapies.
• The HSV treatment landscape is shifting beyond conventional nucleoside analog antivirals toward novel mechanism-based approaches, particularly helicase-primase inhibitors, therapeutic vaccines, and long-acting antiviral strategies targeting improved viral suppression and reduced recurrence.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Herpes Simplex (2022-2036 Forecast)

The HSV treatment market (2022-2036 forecast) comprises nucleoside analog antivirals, helicase-primase inhibitors, therapeutic vaccines, and emerging gene-based therapies, each targeting different aspects of HSV infection and viral persistence.

• Nucleoside analog antivirals: Established therapies such as valacyclovir, and famciclovir remain the standard of care for episodic and suppressive HSV treatment by inhibiting viral DNA replication, although they do not eliminate latent infection.
• Helicase-primase inhibitors: Investigational agents including Pritelivir (AiCuris), ABI-5366, ABI-1179, and Adibelivir (IM-250) represent next-generation antiviral approaches designed to inhibit the HSV helicase-primase complex, with the potential to improve antiviral potency, reduce resistance, and enable long-acting viral suppression.
• Therapeutic vaccines and gene-based therapies: Emerging candidates such as mRNA-based vaccines, monoclonal antibodies, and gene-editing approaches are being developed to enhance immune control, reduce recurrence, and potentially address latent HSV reservoirs.

Currently, nucleoside analog antivirals dominate the commercial HSV market, while helicase-primase inhibitors and advanced immunotherapeutic approaches are driving pipeline innovation and shaping the future treatment landscape.

Herpes Simplex Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the herpes simplex drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in the HSV market is expected to vary based on mechanism of action, clinical differentiation, dosing convenience, and target patient population. Investigational helicase primase inhibitors such as pritelivir are projected to demonstrate relatively faster uptake, driven by their novel mechanism, activity against resistant HSV strains, and significant unmet need in immunocompromised patients with refractory infections. In addition, the potential for improved antiviral efficacy and reduced resistance compared with conventional nucleoside analogs may further support adoption following approval.

In contrast, emerging pipeline candidates such as ABI-5366, ABI-1179, and Adibelivir (IM-250) are expected to follow a more gradual uptake trajectory as additional clinical efficacy, long-term safety, and dosing data become available. Their adoption is likely to be influenced by differentiation in antiviral durability, long-acting suppression potential, and positioning within recurrent HSV management.

Meanwhile, established antivirals including valacyclovir, and famciclovir are expected to maintain significant market share due to their widespread clinical familiarity, generic availability, and established role in suppressive and episodic treatment. However, increasing focus on resistant infections, recurrent disease burden, and next-generation antiviral strategies is expected to gradually reshape the HSV treatment landscape over the forecast period.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in Herpes Simplex

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The United States

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Herpes Simplex Therapies Price Scenario & Trends

Pricing and analogue assessment of herpes simplex therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Herpes Simplex

To keep up with herpes simplex market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the herpes simplex emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in herpes simplex, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at country level. Centers such as the American Social Health Association, US, Institute for Medical Virology, Germany etc. were contacted.Their opinion helps understand and validate current and emerging herpes simplex therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in herpes simplex.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of herpes simplex, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of herpes simplex, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the herpes simplex market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM herpes simplex market.

Report Insights

• Herpes Simplex Patient Population Forecast
• Herpes Simplex Therapeutics Market Size
• Herpes Simplex Pipeline Analysis
• Herpes Simplex Market Size and Trends
• Herpes Simplex Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Herpes Simplex Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Herpes Simplex Treatment Addressable Market (TAM)
• Herpes Simplex Competitive Landscape
• Herpes Simplex Major Companies Insights
• Herpes Simplex Price Trends and Analogue Assessment
• Herpes Simplex Therapies Drug Adoption/Uptake
• Herpes Simplex Therapies Peak Patient Share Analysis

Report Assessment

• Herpes Simplex Current Treatment Practices
• Herpes Simplex Unmet Needs
• Herpes Simplex Clinical Development Analysis
• Herpes Simplex Emerging Drugs Product Profiles
• Herpes Simplex Market attractiveness
• Herpes Simplex Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the herpes simplex market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of herpes simplex?
• What are the disease risks, burdens, and unmet needs of herpes simplex? What will be the growth opportunities across the 7MM concerning the patient population with herpes simplex?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of herpes simplex? What are the current guidelines for treating herpes simplex in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the herpes simplex market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Conferences And Meetings
• 4.3. Key Transactions And Collaborations
• 4.4. News Flow

5. Epidemiology and Market Methodology of Herpes Simplex

6. Herpes Simplex Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of herpes simplex By Therapies (%) in the 7MM in 2025
• 6.3. Market Share of herpes simplex By Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Herpes Simplex

• 7.1. Introduction
• 7.2. Types of Herpes Simplex
• 7.3. Causes and Risk Factors
• 7.4. Pathophysiology
• 7.5. Symptoms and Clinical Presentations
• 7.6. Diagnosis
  • 7.6.1. Diagnostic Algorithm
  • 7.6.2. Diagnostic Guidelines
  • 7.6.3. Differential Diagnosis
• 7.7. Treatment and Management
  • 7.7.1. Treatment Algorithm
  • 7.7.2. Treatment Guidelines
    • 7.7.2.1. WHO Guidelines for the treatment of genital herpes simplex virus
    • 7.7.2.2. UK national guideline for the management of anogenital herpes
    • 7.7.2.3. Centers for Disease Control and Prevention (CDC) Sexually Transmitted Infections Treatment Guidelines

8. Epidemiology and Patient Population of Herpes Simplex

• 8.1. Key Findings
• 8.2. Assumption and Rationale
• 8.3. Diagnosed Cases of HSV in the 7MM
• 8.4. The United States
  • 8.4.1. Total Seroprevalence of HSV in the United States
  • 8.4.2. Total Symptomatic Cases of HSV in the United States
  • 8.4.3. Total Diagnosed Cases of HSV in the United States
  • 8.4.4. Gender-specific Diagnosed Cases of HSV in the United States
  • 8.4.5. Total Recurrent Cases of HSV in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Seroprevalence of HSV in the EU4 and the UK
  • 8.5.2. Total Symptomatic Cases of HSV in the EU4 and the UK
  • 8.5.3. Total Diagnosed Cases of HSV in the EU4 and the UK
  • 8.5.4. Gender-specific Diagnosed Cases of HSV in the EU4 and the UK
  • 8.5.5. Total Recurrent Cases of HSV in the EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Seroprevalence of HSV in the Japan
  • 8.6.2. Total Symptomatic Cases of HSV in the Japan
  • 8.6.3. Total Diagnosed Cases of HSV in the Japan
  • 8.6.4. Gender-specific Diagnosed Cases of HSV in the Japan
  • 8.6.5. Total Recurrent Cases of HSV in the EU4 and the Japan

9. Patient Journey of Herpes Simplex

10. Marketed Therapies

• 10.1. Marketed Competitive Landscape of Herpes Simplex
• 10.2. Amenamevir (AMENALIEF): Maruho
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Summary of Pivotal Trials
  • 10.2.5. Analyst Views

11. Emerging Therapies

• 11.1. Emerging Competitive Landscape of Herpes Simplex
• 11.2. Pritelivir (AIC-316): AiCuris
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
    • 11.2.3.1. Clinical Trial Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst Views
• 11.3. ABI-1179: Assembly Bio
  • 11.3.1. Product Description
  • 11.3.2. Other Developmental Activities
  • 11.3.3. Clinical Development
    • 11.3.3.1. Clinical Trial Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analyst Views

12. Herpes Simplex : Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook of Herpes Simplex
• 12.3. Conjoint Analysis of Herpes Simplex
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Size of Herpes Simplex in the 7MM
• 12.6. The United States
  • 12.6.1. Total Market Size of Herpes Simplex in the United States
  • 12.6.2. Market Size of Herpes Simplex by Therapies in the United States
• 12.7. EU4 and the UK
  • 12.7.1. Total Market Size of Herpes Simplexin EU4 and the UK
  • 12.7.2. Market Size of Herpes Simplex by Therapies in EU4 and the UK
• 12.8. Japan
  • 12.8.1. Total Market Size of Herpes Simplex in Japan
  • 12.8.2. Market Size of Herpes Simplex by Therapies in Japan

13. Unmet Needs of Herpes Simplex

14. SWOT Analysis of Herpes Simplex

15. KOL Views of Herpes Simplex

• 15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement of Herpes Simplex

• 16.1. The US
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025
• 16.5. Market Access and Reimbursement of Herpes Simplex Therapies

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight